Atai Beckley Inc.
HealthcareNASDAQ:ATAI · NASDAQ Global Market
+$0.12 today
Vol 4.97M · Avg 5.66M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-297.5%
avg -108.1%
ROIC
-34.7%
avg -52.3%
ROA
-212.5%
avg -83.6%
Analysis
ROIC is currently the strongest return metric at -34.7% versus its period average of -52.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Srinivas G. Rao | Co-Founder, Chief Executive Officer & Executive Director | $1.10M | — | 57 | $650,794.00 | 0.18% |
Ryan Barrett | Chief Legal & Business Officer | $709,700.00 | — | 45 | $0.00 | <0.01% |
Gerd G. Kochendoerfer | Chief Operating Officer | $679,300.00 | — | 58 | $1.45M | 0.39% |
Kevin Craig | Chief Medical Officer | $615,378.00 | — | 53 | $8,437.00 | <0.01% |
Michael Eric Faerm | Chief Financial Officer | $574,815.00 | — | 59 | $103,000.00 | 0.03% |
Anne Johnson | Chief Accounting Officer | $574,815.00 | — | 57 | $103,000.00 | 0.03% |
Christian Angermayer | Co-Founder & Chairman of the Board | $75,000.00 | — | 48 | $103,000.00 | 0.03% |
Robert Conley | Chief Research & Development Officer | — | — | — | $97,716.00 | 0.03% |
Kavita Panke | Senior Vice President of New Product, Planning & Commercial | — | — | — | — | — |
Glenn Short | Chief Scientific Officer | — | — | 56 | $42,333.00 | 0.01% |
Jason Awe | Vice President of Investor Relations | — | — | — | $64,000.00 | 0.02% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$19.00M
Sells
0
$0.00
Net Sentiment
+$19.00M
Net buying
Most Active
Apeiron Investment Group Ltd.
1 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Aug 14, 2025 | Apeiron Investment Group Ltd. Indirect | Buy | 8.68M | $2.19 | $18,999,999.81 |
Analysis
Insiders reported 1 buys worth $19.00M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $19.00M. Apeiron Investment Group Ltd. was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | +175.4% (7yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Forward estimates point to Revenue at +175.4% (7yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
$3.43B
Enliven Therapeutics, Inc.
NASDAQ:ELVN
$2.81B
Relay Therapeutics, Inc.
NASDAQ:RLAY
$2.59B
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
$1.62B
Inhibrx Biosciences, Inc.
NASDAQ:INBX
$1.35B
Immatics N.V.
NASDAQ:IMTX
$1.26B
Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLX
$1.21B
Nektar Therapeutics
NASDAQ:NKTR
$1.16B
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
$856.09M
Sana Biotechnology, Inc.
NASDAQ:SANA
$745.82M
Who manages ATAI?
Atai Beckley Inc. (ATAI) lists 11 active executives. The top listed executive is Gerd G. Kochendoerfer, Chief Operating Officer.
Are ATAI insiders buying or selling?
Recent insider activity shows net buying of $122.88M.
Explore More
Continue the stock analysis
Jump to another research area for this company.